Dupilumab Versus Omalizumab
Posted Date: Nov 8, 2021
- Investigator: Ahmad Sedaghat
- Specialties: Otolaryngology, Pulmonary Diseases
- Type of Study: Drug
Symptoms of chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma have a large impact on the patients’ quality of life. Symptoms like nasal congestion, loss of sense of smell, and poor lung function negatively affect how people with this condition smell, breathe, and live. Therefore, one of the treatment goals is to reduce those symptoms so that people affected with this condition can experience an improved quality of life. The purpose of this study is to evaluate whether dupilumab works better than omalizumab, two already approved biological drugs for the symptoms of CRSwNP and asthma. This study will evaluate if there is a reduction in nasal polyps and improved sense of smell, as well as a reduction in nasal congestion, improved lung and nasal function, and improved patients’ overall quality of life
Criteria:
Null
Keywords:
Chronic Rhinosinusitis, Comorbid Asthma, Nasal Polyps
For More Information:
Becky Reinert
5132651907
gibsonrk@uc.edu